InvestorsHub Logo
icon url

circuitcity

01/22/20 10:07 AM

#242792 RE: HDGabor #242791

Nice summary, thanks a lot. But what is your implication?

I read as Teva is tough negotiator, but they caved first with Amarin, meaning Amarin ip is very strong.
icon url

rafunrafun

01/22/20 10:08 AM

#242793 RE: HDGabor #242791

They gave up 31 months

Is this what Amarin are trying to prevent, by not settling?

I don't mind giving up cash but the time (x months before TEVA) would bother me, as sales will be in multiple billions.
icon url

roadkilll

01/22/20 10:22 AM

#242797 RE: HDGabor #242791

HDGabor - the dates are important, thanks for posting. A few I like with comparative dates
Linzess approval dates
Aug 30, 2012 FDA approval
Aug 9, 2011 NDA approval

Vascepa
July 26, 2012 FDA approval
It was classified as a Lovaza (me too) drug
2016 The courts interpreted patent law for the FDA and classified as a New Chemical Entity
2019 sNDA approved showing medical benefits FDA had not considered obvious until REDUCE-IT trial was completed and reviewed